Characterization of patients with major psychiatric disorders with AMPA receptor positron emission tomography
- PMID: 39406998
- PMCID: PMC12014498
- DOI: 10.1038/s41380-024-02785-1
Characterization of patients with major psychiatric disorders with AMPA receptor positron emission tomography
Abstract
Synaptic phenotypes in living patients with psychiatric disorders are poorly characterized. Excitatory glutamate α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) is a fundamental component for neurotransmission. We recently developed a positron emission tomography (PET) tracer for AMPAR, [11C]K-2, the first technology to visualize and quantify AMPARs density in living human brain. In this study, we characterized patients with major psychiatric disorders with [11C]K-2. One hundred forty-nine patients with psychiatric disorders (schizophrenia, n = 42; bipolar disorder, n = 37; depression, n = 35; and autism spectrum disorder, n = 35) and 70 healthy participants underwent a PET scan with [11C]K-2 for measurement of AMPAR density. We detected brain regions that showed correlation between AMPAR density and symptomatology scores in each of four disorders. We also found brain areas with significant differences in AMPAR density between patients with each psychiatric disorder and healthy participants. Some of these areas were observed across diseases, indicating that these are commonly affected areas throughout psychiatric disorders. Schizophrenia, bipolar disorder, depression, and autism spectrum disorder are uniquely characterized by AMPAR distribution patterns. Our approach to psychiatric disorders using [11C]K-2 can elucidate the biological mechanisms across diseases and pave the way to develop novel diagnostics and therapeutics based on the synapse physiology.
© 2024. The Author(s).
Conflict of interest statement
Competing interests: TT and TM are the inventors of a patent application for a novel compound that specifically binds to the AMPA receptor (WO 2017006931), including [11C]K-2. TT, TM and TA are the founders and also stockholders of AMPAMETRY, Inc., which holds the exclusive license to use [11C]K-2. No other potential conflicts of interest relevant to this article exist.
Figures





References
-
- Jin H, Mosweu I. The societal cost of schizophrenia: a systematic review. Pharmacoeconomics. 2017;35:25–42. - PubMed
-
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders 5th ed. Wahington, DC: American Psychiatric Publishing; 2013.
-
- Hantouche EG, Akiskal HS, Azorin JM, Châtenet-Duchêne L, Lancrenon S. Clinical and psychometric characterization of depression in mixed mania: a report from the French National Cohort of 1090 manic patients. J Affect Disord. 2006;96:225–32. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical